Business Context and Reporting Period
Company: CryoLife, Inc. (Note: Input metadata referenced "ARTIVION, INC." but the filing text identifies the registrant as CryoLife, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: CryoLife preserves and distributes human tissues (cardiac and vascular) and develops medical devices including surgical adhesives (BioGlue), sealants, and hemostats (HemoStase, PerClot). The company operates two segments: Preservation Services and Medical Devices.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Total Revenues | $28,443 | $87,423 |
| Gross Margin | $15,222 (53.5%) | $50,783 (58.1%) |
| Operating (Loss) Income | $(1,257) | $6,285 |
| Net (Loss) Income | $(3,031) | $1,829 |
| Diluted EPS | $(0.11) | $0.06 |
| Cash and Cash Equivalents | $31,002 | $31,002 (Ending Balance) |
| Net Cash from Operating Activities | N/A | $13,822 |
| Total Debt (Notes Payable) | $405 | $405 |
Note: The company had no outstanding balance on its $14.8 million GE Credit Agreement line of credit as of September 30, 2010.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 1% for the quarter and 5% for the nine-month period compared to 2009. Preservation services revenue grew 1% (quarter) and 7% (nine months), driven by vascular tissue volume. Product revenue grew 3% (quarter) and 4% (nine months), primarily due to HemoStase sales.
- Profitability Decline: The company reported a net loss of $3.0 million for the quarter, compared to a net income of $1.9 million in the prior year quarter. This was driven by significant non-recurring charges.
- Major Charges:
- IPR&D Write-down: $3.7 million charge for acquired in-process research and development related to the Starch Medical (PerClot) transaction.
- Investment Impairment: $3.6 million "other than temporary" impairment charge on the investment in Medafor, Inc. common stock.
- Inventory Write-down: $1.6 million write-down of HemoStase inventory following the termination of the distribution agreement with Medafor.
- Cost of Products: Increased 89% for the quarter and 44% for the nine months, largely due to the HemoStase inventory write-down.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Medafor/HemoStase: Medafor terminated the exclusive distribution agreement (EDA) in September 2010. CryoLife expects to sell remaining HemoStase inventory through March 2011 but anticipates flat or declining revenues in Q4 2010 and Q1 2011 due to market confusion and potential discounts. No further shipments are expected from Medafor.
- Starch Medical/PerClot: CryoLife entered a distribution and license agreement for PerClot (a hemostatic agent) in September 2010. The company plans to file for FDA approval in the U.S. and expects to begin manufacturing in 2011 or 2012. Up to $2.75 million in contingent milestone payments may be due.
- BioGlue: Approved in Japan for aortic dissection repair; sales expected to begin in H1 2011. Domestic sales face competitive pressure and economic constraints.
- Stock Repurchase: The company has repurchased $4.3 million of its common stock under a $15.0 million authorization program.
Risks and Contingencies
- Legal Proceedings: Ongoing litigation with Medafor regarding the termination of the EDA. Medafor has filed counter-claims alleging breach of contract and fraud. CryoLife does not currently estimate a loss range but intends to vigorously defend the claims.
- Regulatory Approval: Future profitability of the PerClot investment depends on obtaining U.S. FDA approval, which is not guaranteed.
- Investment Value: The value of the remaining Medafor investment ($2.6 million) may be subject to further impairment if Medafor's financial condition deteriorates.
- Liquidity: While the company has $31 million in cash, $5 million is restricted under the GE Credit Agreement. The company expects operating cash flow to meet liquidity needs for the next 12 months.
Investor Verification Checklist
- Medafor Litigation Status: Verify the outcome of the lawsuit and counter-claims, as a loss could materially impact profitability.
- HemoStase Inventory Realization: Monitor Q4 2010 and Q1 2011 sales to confirm if the remaining $1.7 million inventory can be sold without further write-downs.
- PerClot Regulatory Timeline: Track the progress of the Investigational Device Exemption (IDE) and Premarket Approval (PMA) with the FDA.
- Deferred Preservation Costs: Review the trend of deferred preservation costs, which decreased by $4.1 million in the first nine months of 2010, to ensure this cash flow benefit is sustainable.
- Stock Repurchase Activity: Monitor the remaining $10.7 million available under the stock repurchase plan and its impact on share count and EPS.